Publications by authors named "Umberto Peretti"

Claim this Profile
E
Exploring external validity of chemotherapy for pancreatic ductal adenocarcinoma in real life.
Michele Reni, Guido Giordano, Marco Audisio, Giulia Orsi, Marina Macchini, Umberto Peretti

Dig Liver Dis· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A pilot study of chlorambucil in pre-treated metastatic pancreatic adenocarcinoma patients bearing germline BRCA or other DNA damage repair system variants.
Catia Carconi, Carlo Bosi, Mario Scartozzi, Massimiliano Cergnul, Marika Cinausero, Umberto Peretti

Pancreatology· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Isolated lung metastases from pancreatic ductal adenocarcinoma (PDAC): Diagnostic and therapeutic challenges of a different disease.
Orsi Giulia, Bandiera Alessandro, Carretta Angelo, Migliori Paolo, Chavez Rosa, Peretti Umberto

Semin Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hypofractionated radiotherapy concomitant to capecitabine after induction chemotherapy for advanced pancreatic adenocarcinoma.
Paolo Passoni, Michele Reni, Sara Broggi, Najla Slim, Andrei Fodor, Umberto Peretti

Clin Transl Radiat Oncol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cyclophosphamide maintenance to extend combination chemotherapy-free interval in metastatic pancreatic ductal adenocarcinoma.
Michele Reni, Umberto Peretti, Marina Macchini, Giulia Orsi, Annamaria Militello

Dig Liver Dis· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Role of Neoadjuvant FOLFIRINOX in Borderline Resectable Pancreatic Cancer: A Network Meta-Analysis.
Fausto Petrelli, Michele Ghidini, Marina Macchini, Giulia Orsi, Umberto Peretti

J Gastrointest Cancer· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA2 genes.
Anna Maria Militello, Giulia Orsi, Alessandro Cavaliere, Monica Niger, Antonio Avallone, Umberto Peretti

Cancer Chemother Pharmacol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv).
Giulia Orsi, Alessandro Cavaliere, Giampaolo Tortora, Sara Lonardi, Marina Macchini, Umberto Peretti

Br J Cancer· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epidemiology and geographic distribution of BRCA1-2 and DNA Damage response genes pathogenic variants in pancreatic ductal adenocarcinoma patients.
Marina Macchini, Federico Centonze, Umberto Peretti, Giulia Orsi, Anna Maria Militello

Cancer Treat Rev· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants.
Marina Macchini, Federico Centonze, Umberto Peretti, Giulia Orsi, Anna Maria Militello

Cancer Treat Rev· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pancreatic Enzyme Replacement Therapy in Patients Undergoing First-Line Gemcitabine Plus -paclitaxel for Advanced Pancreatic Adenocarcinoma.
Ilaria Trestini, Luisa Carbognin, Umberto Peretti, Isabella Sperduti, Alberto Caldart

Front Oncol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multidrug regimens for treatment of older patients with metastatic pancreatic cancer.
Marina Macchini, Marta Chiaravalli, Chiara Pircher, Silvia Zanon, Umberto Peretti

Dig Liver Dis· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring chemotherapy holiday and drugs re-challenge in advanced pancreatic cancer patients.
Marina Macchini, Umberto Peretti, Giulia Orsi, Silvia Zanon, Elena Mazza

Cancer Chemother Pharmacol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time to CA19-9 nadir: a clue for defining optimal treatment duration in patients with resectable pancreatic ductal adenocarcinoma.
Michele Reni, Umberto Peretti, Silvia Zanon, Marina Macchini, Gianpaolo Balzano

Cancer Chemother Pharmacol· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemotherapy in elderly patients with pancreatic cancer: Efficacy, feasibility and future perspectives.
Marina Macchini, Marta Chiaravalli, Silvia Zanon, Umberto Peretti, Elena Mazza

Cancer Treat Rev· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma.
Michele Reni, Silvia Zanon, Gianpaolo Balzano, Paolo Passoni, Chiara Pircher, Umberto Peretti

Eur J Cancer· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial.
Michele Reni, Silvia Zanon, Umberto Peretti, Marta Chiaravalli, Diletta Barone

Lancet Gastroenterol Hepatol· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The personalized medicine for pancreatic ductal adenocarcinoma patients: The oncologist perspective.
Umberto Peretti, Silvia Zanon, Reni Michele

Endosc Ultrasound· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Platelet-derived growth factor receptor inhibitors for non-small cell lung cancer: is the odyssey over?
Luisa Carbognin, Sara Pilotto, Umberto Peretti, Giampaolo Tortora, Emilio Bria

Expert Opin Investig Drugs· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer.
Sara Pilotto, Silvia Novello, Umberto Peretti, Stefania Kinspergher, Ludovica Ciuffreda

Expert Opin Investig Drugs· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune checkpoint inhibitors for non-small-cell lung cancer: does that represent a 'new frontier'?
Sara Pilotto, Stefania Kinspergher, Umberto Peretti, Anna Calio, Luisa Carbognin

Anticancer Agents Med Chem· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk Stratification Model for Resected Squamous-Cell Lung Cancer Patients According to Clinical and Pathological Factors.
Sara Pilotto, Isabella Sperduti, Silvia Novello, Umberto Peretti, Michele Milella

J Thorac Oncol· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma.
Emilio Bria, Sara Pilotto, Eliana Amato, Matteo Fassan, Silvia Novello, Umberto Peretti

Oncotarget· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ALK/EML4 fusion gene may be found in pure squamous carcinoma of the lung.
Anna Caliò, Alessia Nottegar, Eliana Gilioli, Emilio Bria, Sara Pilotto, Umberto Peretti

J Thorac Oncol· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lung adenocarcinoma patient refractory to gefitinib and responsive to crizotinib, with concurrent rare mutation of the epidermal growth factor receptor (L861Q) and increased ALK/MET/ROS1 gene copy number.
Sara Pilotto, Emilio Bria, Umberto Peretti, Francesco Massari, Marina Garassino

J Thorac Oncol· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis